Status:
UNKNOWN
Effect of Rosuvastatin on the Clinical Features of Preeclampsia
Lead Sponsor:
Assiut University
Conditions:
Preeclampsia
Eligibility:
FEMALE
20-35 years
Phase:
PHASE2
Brief Summary
The primary outcome will be the effect of rosuvastatin on the resolution of biochemical features associated with severe PE (↑CRP and IL6). .
Detailed Description
Preeclampsia is a multisystem disorder that complicates 3-5% of pregnancies and remains a major cause of maternal, fetal, and neonatal morbidity and mortality.(1) Preeclampsia is characterized by the...
Eligibility Criteria
Inclusion
- Age: 20-35 years.
- Singleton nonanomalous pregnancy (confirmed with an ultrasound examination).
- Normal lipid profile and normal liver transaminases.
- WBCs (4-11\*103/mm3).
- CRP \< 3 mg/L.
Exclusion
- Parturient's refusal.
- Women with history of cardiac, respiratory, renal, neurologic or endocrine diseases.
- Contraindications for statin therapy (eg, hypersensitivity to rosuvastatin, recent or active liver disease).
- Concomitant therapy with fibrates, niacin, cyclosporine, clarithromycin, or erythromycin.
- Inability to tolerate oral medications secondary to severe nausea and vomiting of pregnancy.
- Multifetal gestation or fetal demise.
- Fetal abnormalities.
- Emergency surgeries.
Key Trial Info
Start Date :
October 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04303806
Start Date
October 1 2020
End Date
December 1 2023
Last Update
March 11 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.